Relative Vaccine Effectiveness of a SARS-CoV-2 mRNA Vaccine Booster Dose Against the Omicron Variant.

Adeel Ajwad ButtVictor B TalisaObaid S ShaikhSaad B OmerFlorian B Mayr

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

While the RVE of SARS-CoV-2 mRNA booster vaccine dose in preventing infection against the Omicron variant is low, the RVE is substantial in preventing hospitalization and high in preventing the most severe/critical disease.

Keyphrases

sars cov
respiratory syndrome coronavirus
randomized controlled trial
systematic review
binding protein
early onset